New Platform for Next-Generation Process Improvements Launched
Nov 09 2018 Read 504 Times
“Merck’s new, adaptive platform of products, applications and expertise will allow customers to bring new therapies to patients in need, faster and more cost-effectively than ever before,” said Udit Batra, member of the Merck Executive Board and CEO, Life Science. “Our unique and holistic approach to next-generation bioprocessing allows us to realise the benefits of process intensification throughout the entire process, not gained by focusing on one area at a time.”
Continuous bioprocessing involves integration of what are typically batch-based, separate manufacturing steps into a connected process, enabling continuous flow from the addition of raw materials through product harvest, purification and testing. Pilot studies suggest that conversion to such a manufacturing method may reduce manufacturing costs by up to 50%.
“We are advancing this industry by improving process economics without sacrificing titer or product quality while minimising waste, energy consumption and raw material use,” Batra added.
While continuous processing is the future of drug manufacturing, customers face challenges today in terms of speed-to-market, facility flexibility or cost of goods. A fully connected, fully continuous process is not necessary for customers to see benefits.
The products, documentation and Merck’s vast knowledge base for application and technical support included with the BioContinuum™ Platform, will help to simplify customers’ processes, save time and prevent risk.
The Life Science business sector of Merck also introduced its expanded Pellicon® Single-Pass Tangential Flow Filtration product, which adds to the purification portfolio of the BioContinuum™ Platform. The application offers intensified purification for more productive, high capacity and cost-effective downstream processes that allow drug manufacturers to meet today’s demands of higher titer and connected or continuous processes.
Merck’s BioContinuum™ Platform represents the evolution in the biopharmaceutical industry, and the company is committed to supporting its customers and the industry throughout the transition.
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Mobile Affinity Sorbent Chromatography Of Proteins - Integration of MS and UV Data for Peak Tracking in HPLC Method Development - VMXm takes its First Users 'wher...
View all digital editions
Apr 23 2019 Moscow, Russia
Apr 30 2019 Chicago, IL, USA
Apr 30 2019 Ricoh Arena, Coventry, UK
May 05 2019 St. Louis, MO, USA
May 13 2019 Fort Worth, Tx, USA